A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...
Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer and continues to be a major cause of cancer ...
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with ...
Hutchmed is accelerating its expansion within the Chinese pharmaceutical landscape, marked by significant clinical and regulatory strides. The company's latest moves, including initiating a pivotal ...
February is Cholangiocarcinoma Awareness Month, a time to shine a light on this disease and the people it affects.
HLB said on the 11th that lirafugratinib, a targeted anticancer drug under development as a treatment for cholangiocarcinoma, showed superior efficacy and safety to existing therapies in a phase 2 ...
LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced new data from a post hoc analysis of the eNRGy trial ...
News Medical on MSN
Diagnostic prognostic and therapeutic relevance of PIVKA-II in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly in regions with ...
Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results